Shiozawa Y, Berry JE, Eber MR, Jung Y, Yumoto K, Cackowski FC, et al. The marrow niche controls the cancer stem cell phenotype of disseminated prostate cancer. Oncotarget. 2016. https://doi.org/10.18632/oncotarget.9251.

Cackowski FC, Taichman RS. Minimal residual disease in prostate Cancer. Adv Exp Med Biol. 2018;1100:47–53. https://doi.org/10.1007/978-3-319-97746-1_3.

Article  PubMed  Google Scholar 

•Cackowski FC, Wang Y, Decker JT, Sifuentes C, Weindorf S, Jung Y, et al. Detection and isolation of disseminated tumor cells in bone marrow of patients with clinically localized prostate cancer. Prostate. 2019;79(14):1715–27. https://doi.org/10.1002/pros.23896. A rigorous investigation of the presence of DTCs in the marrowat the time of prostatectomy.

Begley L, Monteleon C, Shah RB, Macdonald JW, Macoska JA. CXCL12 overexpression and secretion by aging fibroblasts enhance human prostate epithelial proliferation in vitro. Aging Cell. 2005;4(6):291–8.

Article  CAS  PubMed  Google Scholar 

Sun YX, Wang J, Shelburne CE, Lopatin DE, Chinnaiyan AM, Rubin MA, et al. Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem. 2003;89(3):462–73. https://doi.org/10.1002/jcb.10522.

Article  CAS  PubMed  Google Scholar 

Jung Y, Wang J, Lee E, McGee S, Berry JE, Yumoto K, et al. Annexin 2-CXCL12 interactions regulate metastatic cell targeting and growth in the bone marrow. Mol Cancer Res. 2015;13(1):197–207. https://doi.org/10.1158/1541-7786.MCR-14-0118.

Article  CAS  PubMed  Google Scholar 

•McFarlane A, Pohler E, Moraga I. Molecular and cellular factors determining the functional pleiotropy of cytokines. FEBS J. 2023;290(10):2525–52. https://doi.org/10.1111/febs.16420. Discussion of ligand-receptor binding affinity and topology, signaling protein levels contribute to the modulation and diversification of cytokine responses.

Dinarello CA. Historical insights into cytokines. Eur J Immunol. 2007;37(Suppl 1):S34–45. https://doi.org/10.1002/eji.200737772.

Article  CAS  PubMed  PubMed Central  Google Scholar 

••Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–7. https://doi.org/10.1038/nature01322. A seminal paper frequently cited exploring the causal relationship between inflammation, innate immunity and cancer probing the molecular and cellular mechanisms mediating this relationships.

•Ihle JN. Cytokine receptor signalling. Nature. 1995;377(6550):591–4. https://doi.org/10.1038/377591a0. Formative summary work outlining the relationships between cytokine receptor superfamilies, Janus kinases (JAKs) and signal transducers and activators of transcription (STATs). These signaling pathways diversify cytokine responses.

Pedersen EA, Shiozawa Y, Pienta KJ, Taichman RS. The prostate cancer bone marrow niche: more than just ‘fertile soil’. Asian J Androl. 2012;14(3):423–7. https://doi.org/10.1038/aja.2011.164.

Article  PubMed  PubMed Central  Google Scholar 

Culig Z. Interleukin-6 function and targeting in prostate Cancer. Adv Exp Med Biol. 2021;1290:1–8. https://doi.org/10.1007/978-3-030-55617-4_1.

Article  CAS  PubMed  Google Scholar 

•Harshman LC, Wang VX, Hamid AA, Santone G, Drake CG, Carducci MA, et al. Impact of baseline serum IL-8 on metastatic hormone-sensitive prostate cancer outcomes in the phase 3 CHAARTED trial (E3805). Prostate. 2020;80(16):1429–37. https://doi.org/10.1002/pros.24074. This paper describes how elevated serum   terleukin-8 (IL-8) at androgen deprivation therapy (ADT) start predicted poorer overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC) patients. Serum IL-8 levels were associated with shorter time to castration-resistant prostate cancer (CRPC). Targeting IL-8 may improve mHSPC outcomes, independent of docetaxel use or metastatic burden.

Olivas A, Price RS. Obesity, inflammation, and advanced prostate Cancer. Nutr Cancer. 2021;73(11–12):2232–48. https://doi.org/10.1080/01635581.2020.1856889.

Article  CAS  PubMed  Google Scholar 

Kim JK, Chang I, Jung Y, Kaplan Z, Hill EE, Taichman RS, et al. Mycoplasma hyorhinis infection promotes TNF-α signaling and SMAC mimetic-mediated apoptosis in human prostate cancer. Heliyon. 2023;9(10):e20655. https://doi.org/10.1016/j.heliyon.2023.e20655.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li Y, Zhang B, Xiang L, Xia S, Kucuk O, Deng X, et al. TGF-β causes Docetaxel resistance in prostate Cancer via the induction of Bcl-2 by acetylated KLF5 and protein stabilization. Theranostics. 2020;10(17):7656–70. https://doi.org/10.7150/thno.44567.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Esposito M, Fang C, Cook KC, Park N, Wei Y, Spadazzi C, et al. TGF-β-induced DACT1 biomolecular condensates repress wnt signalling to promote bone metastasis. Nat Cell Biol. 2021;23(3):257–67. https://doi.org/10.1038/s41556-021-00641-w.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mirzaei S, Paskeh MDA, Saghari Y, Zarrabi A, Hamblin MR, Entezari M, et al. Transforming growth factor-beta (TGF-β) in prostate cancer: a dual function mediator? Int J Biol Macromol. 2022;206:435–52. https://doi.org/10.1016/j.ijbiomac.2022.02.094.

Article  CAS  PubMed  Google Scholar 

Archer M, Dogra N, Kyprianou N. Inflammation as a driver of prostate Cancer metastasis and therapeutic resistance. Cancers (Basel). 2020;12(10). https://doi.org/10.3390/cancers12102984.

Cheng K, Batbatan C, Jia Q. IL-6 enhances the viability and Invasion ability of prostate Cancer cells. Stud Health Technol Inf. 2023;308:521–6. https://doi.org/10.3233/shti230879.

Article  Google Scholar 

Deichaite I, Sears TJ, Sutton L, Rebibo D, Morgan K, Nelson T, et al. Differential regulation of TNFα and IL-6 expression contributes to immune evasion in prostate cancer. J Transl Med. 2022;20(1):527. https://doi.org/10.1186/s12967-022-03731-x.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hu YM, Lou XL, Liu BZ, Sun L, Wan S, Wu L, et al. TGF-β1-regulated mir-3691-3p targets E2F3 and PRDM1 to inhibit prostate cancer progression. Asian J Androl. 2021;23(2):188–96. https://doi.org/10.4103/aja.aja_60_20.

Article  CAS  PubMed  Google Scholar 

Daouk R, Bahmad HF, Saleh E, Monzer A, Ballout F, Kadara H, et al. Genome-wide gene expression analysis of a murine model of prostate cancer progression: deciphering the roles of IL-6 and p38 MAPK as potential therapeutic targets. PLoS One. 2020;15(8):e0237442. https://doi.org/10.1371/journal.pone.0237442.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ganaie AA, Mansini AP, Hussain T, Rao A, Siddique HR, Shabaneh A, et al. Anti-S100A4 antibody therapy is efficient in treating aggressive prostate Cancer and reversing immunosuppression: serum and biopsy S100A4 as a clinical predictor. Mol Cancer Ther. 2020;19(12):2598–611. https://doi.org/10.1158/1535-7163.Mct-20-0410.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang ZH, Liu MD, Yao K, Xu S, Yu DX, Xie DD, et al. Vitamin D deficiency aggravates growth and metastasis of prostate cancer through promoting EMT in two β-catenin-related mechanisms. J Nutr Biochem. 2023;111:109177. https://doi.org/10.1016/j.jnutbio.2022.109177.

Article  CAS  PubMed  Google Scholar 

Łabędź W, Przybyla A, Zimna A, Dąbrowski M, Kubaszewski Ł. The role of cytokines in the Metastasis of Solid Tumors to the spine: systematic review. Int J Mol Sci. 2023;24(4). https://doi.org/10.3390/ijms24043785.

Quante M, Tu SP, Tomita H, Gonda T, Wang SS, Takashi S, et al. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell. 2011;19(2):257–72.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ostman A, Augsten M. Cancer-associated fibroblasts and tumor growth–bystanders turning into key players. Curr Opin Genet Dev. 2009;19(1):67–73. https://doi.org/10.1016/j.gde.2009.01.003.

Article  CAS  PubMed  Google Scholar 

Zhang B, Li Y, Wu Q, Xie L, Barwick B, Fu C, et al. Acetylation of KLF5 maintains EMT and tumorigenicity to cause chemoresistant bone metastasis in prostate cancer. Nat Commun. 2021;12(1):1714. https://doi.org/10.1038/s41467-021-21976-w.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sadrkhanloo M, Paskeh MDA, Hashemi M, Raesi R, Motahhary M, Saghari S, et al. STAT3 signaling in prostate cancer progression and therapy resistance: an oncogenic pathway with diverse functions. Biomed Pharmacother. 2023;158:114168. https://doi.org/10.1016/j.biopha.2022.114168.

Article  CAS  PubMed  Google Scholar 

Armstrong AJ, Nixon AB, Carmack A, Yang Q, Eisen T, Stadler WM, et al. Angiokines Associated with targeted therapy outcomes in patients with Non-clear Cell Renal Cell Carcinoma. Clin Cancer Res. 2021;27(12):3317–28. https://doi.org/10.1158/1078-0432.Ccr-20-4504.

Article  CAS  PubMed  Google Scholar 

Macías M, García-Cortés Á, Torres M, Ancizu-Marckert J, Ignacio Pascual J, Díez-Caballero F, et al. Characterization of the perioperative changes of exosomal immune-related cytokines induced by prostatectomy in early-stage prostate cancer patients. Cytokine. 2021;141:155471. https://doi.org/10.1016/j.cyto.2021.155471.

Article  CAS  PubMed  Google Scholar 

Runcie KD, Dallos MC. Prostate Cancer Immunothera